Search Page

1

Cite

Share

The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.

Periman LM, Perez VL, Saban DR, Lin MC, Neri P. Periman LM, et al. Among authors: neri p. J Ocul Pharmacol Ther. 2020 Apr;36(3):137-146. doi: 10.1089/jop.2019.0060. Epub 2020 Mar 12. J Ocul Pharmacol Ther. 2020. PMID: 32175799 Free PMC article. Review.

Cite

Share

2

Cite

Share

New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review.

Rosenbaum JT, Bodaghi B, Couto C, Zierhut M, Acharya N, Pavesio C, Tay-Kearney ML, Neri P, Douglas K, Pathai S, Song AP, Kron M, Foster CS. Rosenbaum JT, et al. Among authors: neri p. Semin Arthritis Rheum. 2019 Dec;49(3):438-445. doi: 10.1016/j.semarthrit.2019.06.004. Epub 2019 Jun 10. Semin Arthritis Rheum. 2019. PMID: 31301816 Free article. Review.

Cite

Share

3

Cite

Share

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.

Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, Dimopoulos M, Kulakova M, Lam A, Hashim M, He J, Heeg B, Ukropec J, Vermeulen J, Cote S, Bahlis N. Munshi NC, et al. Among authors: neri p. Blood Adv. 2020 Dec 8;4(23):5988-5999. doi: 10.1182/bloodadvances.2020002827. Blood Adv. 2020. PMID: 33284948 Free PMC article.

Cite

Share

4

Cite

Share

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.

Gooding S, Ansari-Pour N, Towfic F, Ortiz Estévez M, Chamberlain PP, Tsai KT, Flynt E, Hirst M, Rozelle D, Dhiman P, Neri P, Ramasamy K, Bahlis N, Vyas P, Thakurta A. Gooding S, et al. Among authors: neri p. Blood. 2021 Jan 14;137(2):232-237. doi: 10.1182/blood.2020007081. Blood. 2021. PMID: 33443552 Free PMC article.

Cite

Share

5

Cite

Share

Choroidal biomarkers.

Pichi F, Aggarwal K, Neri P, Salvetti P, Lembo A, Nucci P, Gemmy Cheung CM, Gupta V. Pichi F, et al. Among authors: neri p. Indian J Ophthalmol. 2018 Dec;66(12):1716-1726. doi: 10.4103/ijo.IJO_893_18. Indian J Ophthalmol. 2018. PMID: 30451172 Free PMC article. Review.

Cite

Share

6

Cite

Share

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

Bahlis NJ, Sutherland H, White D, Sebag M, Lentzsch S, Kotb R, Venner CP, Gasparetto C, Del Col A, Neri P, Reece D, Kauffman M, Shacham S, Unger TJ, Jeha J, Saint-Martin JR, Shah J, Chen C. Bahlis NJ, et al. Among authors: neri p. Blood. 2018 Dec 13;132(24):2546-2554. doi: 10.1182/blood-2018-06-858852. Epub 2018 Oct 23. Blood. 2018. PMID: 30352784 Free PMC article. Clinical Trial.

Cite

Share

7

Cite

Share

Association of Ocular Adverse Events With Inactivated COVID-19 Vaccination in Patients in Abu Dhabi.

Pichi F, Aljneibi S, Neri P, Hay S, Dackiw C, Ghazi NG. Pichi F, et al. Among authors: neri p. JAMA Ophthalmol. 2021 Oct 1;139(10):1131-1135. doi: 10.1001/jamaophthalmol.2021.3477. JAMA Ophthalmol. 2021. PMID: 34473209

Cite

Share

8

Cite

Share

Genetic of uveitis.

Pichi F, Carrai P, Srivastava SK, Lowder CY, Nucci P, Neri P. Pichi F, et al. Among authors: neri p. Int Ophthalmol. 2016 Jun;36(3):419-33. doi: 10.1007/s10792-015-0136-9. Epub 2015 Oct 9. Int Ophthalmol. 2016. PMID: 26453112 Review.

Cite

Share

9

Cite

Share

New pharmacotherapy options for noninfectious posterior uveitis.

Pleyer U, Neri P, Deuter C. Pleyer U, et al. Among authors: neri p. Int Ophthalmol. 2021 Jun;41(6):2265-2281. doi: 10.1007/s10792-021-01763-8. Epub 2021 Feb 25. Int Ophthalmol. 2021. PMID: 33634341 Free PMC article. Review.

Cite

Share

10

Cite

Share

Treatment of Relapsed/Refractory Multiple Myeloma.

Neri P, Bahlis NJ, Paba-Prada C, Richardson P. Neri P, et al. Cancer Treat Res. 2016;169:169-194. doi: 10.1007/978-3-319-40320-5_10. Cancer Treat Res. 2016. PMID: 27696263 Review.

Cite

Share